Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-045921
Filing Date
2024-11-14
Accepted
2024-11-14 16:25:34
Documents
72
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1758660
2 ex31-1.htm EX-31.1 15310
3 ex32-1.htm EX-32.1 6870
  Complete submission text file 0001493152-24-045921.txt   9066816

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE qlgn-20240930.xsd EX-101.SCH 73164
5 XBRL CALCULATION FILE qlgn-20240930_cal.xml EX-101.CAL 66925
6 XBRL DEFINITION FILE qlgn-20240930_def.xml EX-101.DEF 340322
7 XBRL LABEL FILE qlgn-20240930_lab.xml EX-101.LAB 546815
8 XBRL PRESENTATION FILE qlgn-20240930_pre.xml EX-101.PRE 437009
74 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1661225
Mailing Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011
Business Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011 (760) 918-9165
Qualigen Therapeutics, Inc. (Filer) CIK: 0001460702 (see all company filings)

EIN.: 263474527 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37428 | Film No.: 241462907
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)